Page 194 - Educacional Ponenecias Congreso SEHH-STH 2020

cundarios, mejorar la calidad de vida y evitar pautar tratamientos que puede que no sean imprescindibles.
❯ Bibliografía
1. Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin He- matol. 2010;47:302-11.
2. Mahon FX.Treatment-free remission in CML: who, how, and why?. Hematology Am Soc Hematol Educ Program. 2017;2017(1):102-9.
3. Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year sur- vival results of the randomized CML study IV and impact of non- CML determinants. Leukemia. 2017;31:2398-406.
4. Breccia M, Foà R. Current Information and Recommendations on the Dis- continuation of TKI Inhibitors in Chronic Myeloid Leukemia. Curr Oncol Rep. 2018;20(3):23.
5. Sharf G, Marín C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34(8):2102-12.
6. Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second- generation tyrosine kinase inhibitors. Am J Hematol. 2019;94(3):346-57.
7. Villemagne Sanchez LA, O’Callaghan C, Gough K, Hall K, Kashima Y, Seymour
JF, et al. Patient perceptions of treatment-free remission in chronic myeloid
leukemia. Leuk Lymphoma. 2018 Feb;59(2):406-15.
8. Saglio G, Gale RP. Prospects for achieving treatment-free remission in chronic
myeloid leukaemia. Br J Haematol. 2020;190(3):318-27.
9. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84.
10. MahonFX,RéaD,GuilhotJ,GuilhotF,HuguetF,NicoliniF,etal.Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010 Nov;11(11):1029-35.
11. Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second- gener- ation tyrosine kinase inhibitors. Am J Hematol. 2019;94:346-57.
12. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et
al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, mul- ticentre, non-randomised, trial. Lancet Oncol. 2018 Jun;19(6):747-57.
13. Harrington P, Radia D, de Lavallade H. What are the considerations for tyro- sine kinase inhibitor discontinuation in chronic-phase chronic myeloid leu- kemia? Expert Rev Hematol. 2020 Mar;13(3):213-22.
14. Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104:1589-96.
15. Shen N,You Y, Zhong ZD, Meng L, Zhou JF, Zou P, et al. Monitoring and Analysis of Chinese Chronic Myeloid Leukemia Patients Who Have Stopped Tyrosine Kinase Inhibitor Therapy. Curr Med Sci. 2019;39:211-6.
16. Hernández-Boluda JC, Pereira A, Pastor-Galán I, Álvarez-Larrán A, Savchuk A, Puerta JM, et al. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: result from a nationwide series of 234 patients. Blood Cancer J. 2018;8(10):91.
LXII Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
194